348 related articles for article (PubMed ID: 33717226)
1. Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors.
Kim H; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim KM; Kim ST
Ther Adv Med Oncol; 2021; 13():1758835921992992. PubMed ID: 33717226
[TBL] [Abstract][Full Text] [Related]
2. The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors.
Kim H; Ahn S; Kim H; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim KM; Kim ST
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2427-2435. PubMed ID: 34510272
[TBL] [Abstract][Full Text] [Related]
3. Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer.
Kim H; Kim H; Kim R; Jo H; Kim HR; Hong J; Park JO; Park YS; Kim ST
Technol Cancer Res Treat; 2021; 20():15330338211062324. PubMed ID: 34855561
[No Abstract] [Full Text] [Related]
4. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.
Wu Y; Xu J; Du C; Wu Y; Xia D; Lv W; Hu J
Front Oncol; 2019; 9():1161. PubMed ID: 31750249
[No Abstract] [Full Text] [Related]
5. The clinical utility of tumor mutational burden in non-small cell lung cancer.
Greillier L; Tomasini P; Barlesi F
Transl Lung Cancer Res; 2018 Dec; 7(6):639-646. PubMed ID: 30505708
[TBL] [Abstract][Full Text] [Related]
6. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
[TBL] [Abstract][Full Text] [Related]
7. Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.
Xu Y; Li H; Huang Z; Chen K; Yu X; Sheng J; Zhang HH; Fan Y
Transl Lung Cancer Res; 2020 Dec; 9(6):2367-2379. PubMed ID: 33489799
[TBL] [Abstract][Full Text] [Related]
8. Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer.
Kim J; Kim B; Kang SY; Heo YJ; Park SH; Kim ST; Kang WK; Lee J; Kim KM
Front Oncol; 2020; 10():314. PubMed ID: 32232003
[No Abstract] [Full Text] [Related]
9. SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases.
Li Y; Yang X; Zhu W; Xu Y; Ma J; He C; Wang F
Cancer Cell Int; 2022 Nov; 22(1):347. PubMed ID: 36371186
[TBL] [Abstract][Full Text] [Related]
10. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
Front Immunol; 2021; 12():751407. PubMed ID: 34659255
[TBL] [Abstract][Full Text] [Related]
11. Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors.
Xavier CB; Lopes CDH; Awni BM; Campos EF; Alves JPB; Camargo AA; Guardia GDA; Galante PAF; Jardim DL
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358851
[TBL] [Abstract][Full Text] [Related]
12. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
13. High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis.
Jung J; Heo YJ; Park S
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37094985
[TBL] [Abstract][Full Text] [Related]
14. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
15. Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies.
Mazloom A; Ghalehsari N; Gazivoda V; Nimkar N; Paul S; Gregos P; Rateshwar J; Khan U
J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32781500
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Yoh K; Matsumoto S; Furuya N; Nishino K; Miyamoto S; Oizumi S; Okamoto N; Itani H; Kuyama S; Nakamura A; Nishi K; Fukuda I; Tsuta K; Hayashi Y; Motoi N; Ishii G; Goto K
Lung Cancer; 2021 Sep; 159():128-134. PubMed ID: 34333203
[TBL] [Abstract][Full Text] [Related]
17. The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis.
Cao J; Yang X; Chen S; Wang J; Fan X; Fu S; Yang L
Transl Oncol; 2022 Jun; 20():101375. PubMed ID: 35339028
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy.
Wang S; Fang Y; Jiang N; Xing S; Li Q; Chen R; Yi X; Zhang Z; Li N
Front Immunol; 2021; 12():631483. PubMed ID: 33732253
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score.
Cho YA; Lee H; Kim DG; Kim H; Ha SY; Choi YL; Jang KT; Kim KM
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572886
[TBL] [Abstract][Full Text] [Related]
20. The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis.
Ning B; Liu Y; Wang M; Li Y; Xu T; Wei Y
Front Pharmacol; 2022; 13():748674. PubMed ID: 35355708
[No Abstract] [Full Text] [Related]
[Next] [New Search]
